Stockreport

ProSomnus Severe Indication 510(k) Submission Accepted for Review by the FDA

ProSomnus, Inc.  (OSA) 
PDF PLEASANTON, Calif., Jan. 30, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA) (the “Company”), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy™, annou [Read more]